SREBF1 and metabolic dysfunction-associated steatotic liver disease: The present study showed that PNPLA3 inhibitors can decrease DNL by potentiating AMPK activity and decreasing SREBP-1c expression, further highlighting the potential of targeting lipid metabolism pathways for NAFLD management.